NCT01395784 - Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

January 31, 2014

Study Completion Date

April 30, 2014

Conditions

Opioid Abuse

Interventions

DRUG

pioglitazone

A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.

Trial Locations (1)

10032

Columbia Univ/ NYSPI Division on Substance Abuse, New York